Alnylam Pharmaceuticals Inc (ALNY.OQ)
ALNY.OQ on NASDAQ Stock Exchange Global Select Market
82.07USD
18 Apr 2019
82.07USD
18 Apr 2019
Change (% chg)
$-2.82 (-3.32%)
$-2.82 (-3.32%)
Prev Close
$84.89
$84.89
Open
$85.06
$85.06
Day's High
$86.00
$86.00
Day's Low
$79.90
$79.90
Volume
474,747
474,747
Avg. Vol
294,122
294,122
52-wk High
$124.15
$124.15
52-wk Low
$60.28
$60.28
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Dec '18 | 21.03 | -2.092 |
| Sep '18 | 2.07 | -2.434 | |
| Jun '18 | 29.91 | -1.627 | |
| Mar '18 | 21.90 | -1.420 | |
| FY 2017 | Dec '17 | 37.92 | -1.479 |
| Sep '17 | 17.10 | -1.339 | |
| Jun '17 | 15.93 | -1.344 | |
| Mar '17 | 18.96 | -1.247 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-19 | 14 | 33.84 | 80.71 | 18.00 | 76.98 |
| Quarter Ending Sep-19 | 14 | 44.65 | 113.45 | 25.00 | 96.80 |
| Year Ending Dec-19 | 17 | 162.16 | 396.08 | 94.00 | 340.49 |
| Year Ending Dec-20 | 17 | 429.50 | 874.74 | 253.00 | 665.97 |
| Earnings (per share) | |||||
| Quarter Ending Jun-19 | 15 | -2.07 | -1.69 | -2.52 | -1.49 |
| Quarter Ending Sep-19 | 15 | -2.05 | -1.66 | -2.43 | -1.37 |
| Year Ending Dec-19 | 16 | -8.52 | -6.90 | -9.85 | -5.58 |
| Year Ending Dec-20 | 15 | -6.93 | -3.72 | -8.52 | -3.10 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 69.30 | 32.55 | |
| P/E High - Last 5 Yrs. | -- | 147.69 | 48.10 | |
| P/E Low - Last 5 Yrs. | -- | 47.94 | 23.42 | |
| Beta | 2.97 | 1.08 | 0.87 | |
| Price to Sales (TTM) | 170.48 | 49.51 | 8.39 | |
| Price to Book (MRQ) | 10.02 | 10.13 | 5.27 | |
| Price to Tangible Book (MRQ) | 10.02 | 13.74 | 6.74 | |
| Price to Cash Flow (TTM) | -- | 56.16 | 24.12 | |
| % Owned Institutions | 96.38 | 3.71 | 1.65 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.12 | 1.35 | |
| Dividend Yield - 5 Year Avg | -- | 0.09 | 1.37 | |
| Dividend 5 Year Growth Rate | -- | 0.78 | 4.70 | |
| Payout Ratio(TTM) | -- | 7.02 | 39.61 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 82.94 | 206.06 | 13.46 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 120.51 | 49.00 | 8.04 | |
| Sales - 5 Yr. Growth Rate | -10.64 | 22.77 | 10.85 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -27.58 | 75.31 | 47.73 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -20.86 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 11.97 | 10.46 | |
| Capital Spending - 5 Yr. Growth Rate | 118.68 | 9.11 | 14.68 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.24 | 2.18 |
| Current Ratio (MRQ) | 8.84 | 3.57 | 2.98 |
| LT Debt to Equity (MRQ) | 13.36 | 18.63 | 11.32 |
| Total Debt to Equity (MRQ) | 13.36 | 31.30 | 16.01 |
| Interest Coverage (TTM) | -- | -43.11 | 28.44 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 56.27 | 52.41 | |
| Gross Margin - 5 Yr. Avg. | -- | 60.50 | 50.39 | |
| EBITD Margin (TTM) | -661.41 | -- | -- | |
| EBITD - 5 Yr. Avg | -480.35 | -110.67 | 12.41 | |
| Operating Margin (TTM) | -680.48 | -184.95 | 5.77 | |
| Operating Margin - 5 Yr. Avg. | -533.41 | -127.15 | 8.01 | |
| Pre-Tax Margin (TTM) | -670.81 | -175.66 | 4.79 | |
| Pre-Tax Margin - 5 Yr. Avg. | -518.10 | -132.94 | 8.29 | |
| Net Profit Margin (TTM) | -670.81 | -182.37 | 1.52 | |
| Net Profit Margin - 5 Yr. Avg. | -496.94 | -137.34 | 4.70 | |
| Effective Tax Rate (TTM) | -- | 22.47 | 22.13 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 15.50 | 22.58 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 128,399 | 7,653,406 | 820,412,550 | |
| Net Income/Employee (TTM) | -861,313 | 513,605 | 92,866,182 | |
| Receivable Turnover (TTM) | 5.30 | 6.28 | 5.82 | |
| Inventory Turnover (TTM) | -- | 1.89 | 3.41 | |
| Asset Turnover (TTM) | 0.05 | 0.32 | 0.90 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -31.44 | 6.38 | 10.60 | |
| Return on Assets - 5 Yr. Avg. | -31.82 | 5.47 | 11.78 | |
| Return on Investment (TTM) | -33.58 | 8.91 | 13.83 | |
| Return on Investment - 5 Yr. Avg. | -35.07 | 6.79 | 15.32 | |
| Return on Equity (TTM) | -39.86 | 10.06 | 15.25 | |
| Return on Equity - 5 Yr. Avg. | -40.19 | 8.32 | 16.41 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 14.75 | -0.01 | -10.64 |
| EPS (TTM) % | -38.73 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Alnylam Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 66.44 | 60.70 | 99 | 99 |
| 13 Week | 45.87 | 38.77 | 99 | 95 |
| 26 Week | 152.83 | 133.61 | 99 | 97 |
| 52 Week | 238.72 | 187.09 | 99 | 69 |
| YTD | 227.59 | 187.69 | 99 | 72 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- UPDATE 2-Regeneron forays into gene-silencing therapies with Alnylam tie-up
- Alnylam, Regeneron to partner for RNAi treatments
- UPDATE 2-Side effects of Alnylam's gene-silencing drug raise concerns, shares slip
- Alnylam's gene-silencing drug meets main goal in late-stage study
- Eli Lilly makes bet on gene-silencing drug firm Dicerna
Institutional Holders
| % Shares Owned: | 88.19% |
| # of Holders: | 437 |
| Total Shares Held: | 93,864,271 |
| 3 Mo. Net Change: | -8,470 |
| # New Positions: | 4 |
| # Closed Positions: | 7 |
| # Increased Positions: | 25 |
| # Reduced Positions: | 22 |
| # Net Buyers: | 3 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.